Trial Profile
Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot evaluation of therapeutic drug monitoring (TDM)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Ritonavir (Primary) ; Tipranavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TICINO
- Sponsors Boehringer Ingelheim Pharma KG; Boehringer Ingelheim Pharmaceuticals
- 08 Apr 2022 This trial has been completed in Spain (End Date: 8 Oct 2008), according to European Clinical Trials Database record.
- 28 Jun 2012 Additional location (Portugal) added and official title amended as reported by European Clinical Trials Database.
- 28 Nov 2008 Actual patient number reported as 11; actual end date reported as October 2008 by ClinicalTrials.gov.